Onkologie. 2021:15(3):139-144 | DOI: 10.36290/xon.2021.027
ALK-driven non-small cell lung cancer: prevention, prophylaxis, and treatment of brain metastases
- Klinika pneumologie a ftizeologie, Fakultní nemocnice Plzeň
The author presents case reports of two patients who have been receiving long-term treatment for advanced ALK-driven lung adenocarcinoma with the use of a number of therapeutic modalities including several lines of chemotherapy. The first patient received several lines of systemic treatment and palliative brain irradiation; the other patient had lung surgery and mediastinal irradiation as well as surgery for brain metastasis; both patients were successively treated with crizotinib and ceritinib, and have now been on treatment with alectinib for more than three years. They both underwent repeat treatment for small brain metastases using the Leksell gamma knife. The two patients have been alive for more than 13 and 10 years since diagnosis, respectively.
Keywords: non-small cell lung cancer, EML-4-ALK translocation, targeted therapy, crizotinib, ceritinib, alectinib, chemotherapy, radiotherapy,
Published: May 6, 2021 Show citation
References
- Pešek M, et al. Pneumoonkologie v kazuistikách. Praha: Maxdorf, pozorování 47, s. 189.
- Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017; 377: 829-838
Go to original source... 
Go to PubMed... - Gadgeel S, Peters S, Mok T, et al. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALKþ) non-small-cell lung cancer: CNS efficacy results from the ALEX study. Ann Oncol. 2018; 29: 2214-2222. Go to original source... Go to PubMed...
- Mok T, Camidge DR, Gadgeel SM, Rosell R, Dziadziuszko R, Kim DW, Pérol M, Ou SI, Ahn JS, Shaw AT, Bordogna W, Smoljanović V, Hilton M, Ruf T, Noé J, Peters S. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol. 2020 Aug; 31(8): 1056-1064. Go to original source... Go to PubMed...
- Tomasini P, et al. Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases. Ther Adv Respir Dis. 2019 Jan-Dec; 13:1753466619831906. Go to original source... Go to PubMed...